Little Green Pharma Limited

Psilocybin And MDMA Down- Scheduled

LGP’s psychedelics subsidiary Reset Mind Sciences welcomes the TGA’s decision to down-schedule psilocybin and MDMA

Little Green Pharma (ASX: LGP) and its psychedelics focused subsidiary Reset Mind Sciences Limited (“Reset Mind Sciences”) welcome Friday’s decision by the Therapeutic Goods Administration (“TGA”) to change the classification of psilocybin and MDMA to allow prescribing by authorised psychiatrists.

A copy of the media release is available here: classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists

The announcement means Australia will become the first market in the world to recognise psychedelics as medicines and paves the way for the use of psilocybin for the treatment of treatment resistant depression and MDMA for PTSD outside of a clinical trial environment from 1 July 2023.

The TGA’s decision to re-classify psilocybin and MDMA has come significantly earlier than expected by industry, given the TGA’s decision in late December 2021 not to reclassify and limit use to clinical trials only. However, the unexpected change uniquely positions Reset compared to other psychedelic companies in Australia given both its Schedule 9 licence, authorizing it to cultivate and supply psilocybin, and its impending clinical trial, enabling Reset to validate its treatment protocols for the use of psilocybin in connection with treatment resistant depression. These developments now allow Reset to accelerate and implement its commercialisation plans far earlier than expected.

Reset Mind Sciences CEO Mr. Shaun Duffy said, “The announcement by the TGA is truly ground- breaking in the field of psychedelics and I welcome their decision. There is a significant body of research emerging in Australia and globally for the use of psychedelics to treat mental health conditions and this decision allows the use of these drugs for the mental health conditions that have demonstrated the most potential in the research.”

Reset Mind Sciences is in the advanced stages of preparations for a Perth based clinical trial using psilocybin for treatment resistant depression, the condition the TGA has identified as permissible for treatment under its prescribed parameters.

Mr. Duffy said, ”We have put more than 18 months of detailed planning into our trial with a focus on testing, refining and developing the therapy protocols that go along with the administration of psilocybin. This is a specialised field of expertise in itself that should not be underestimated and our trial provides an environment to optimise our protocols. We have assembled an outstanding team of therapists that are trained and ready to go once we finalise the ethics approval process. Given the comments from the Ethics Committee to date we hope and expect that’s not far away.”

The trial’s Principal Investigator is the University of Western Australia’s Professor Sean Hood who will have oversight of responsible governance and treatment delivery.

Itisincumbenton the industry to proceed in a professional and responsible manner with this treatment and ensure those administering it have the necessary skills” added Mr Duffy.

In addition, Reset Mind Sciences is in the final stages of commissioning construction of a bespoke mushroom cultivation facility which is expected to be on site at LGP’s existing cannabis cultivation facility in the coming weeks. Reset is one of a very limited number of Australian companies legally permitted to cultivate psilocybin containing mushrooms. Reset’s objective is to be able to produce GMP grade psilocybin from its mushrooms as soon as possible.

Mr. Duffy added, “Reset is fortunate that its clinical trial indication focus on treatment resistant depression matches the TGA’s psilocybin policy, as well as deciding to obtain a Schedule 9 supply and manufacturing licence in 2019 to enable progress of its inhouse psilocybin production capability. We believe the advanced stage of Reset’s treatment ecosystem puts the company in a strong leadership position for this significant therapeutic development.

We’re still working through the full implications of the TGA’s decision for our strategy moving forward but suffice to say it’s a very positive development for us and will result in an acceleration of our plans.”

Little Green Pharma has previously announced its intention to demerge Reset by way of an in- specie distribution of its current ownership out to its shareholder base. If approved by LGP shareholders, the effect would be that eligible LGP shareholders on a certain record date (to be determined) would receive a separate direct shareholding in Reset Mind Sciences and the opportunity to invest additional funds into it.

Given this regulatory development and that Reset is on the precipiceof becoming operational on both the clinical trial and cultivation fronts, we believe the time is right to move ahead with the demerger of Reset Mind Sciences from Little Green Pharma into a standalone dedicated psychedelics company.”

Click here for the full ASX Release

This article includes content from Little Green Pharma, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Melodiol Global Health Limited

Corporate Update

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to provide the following corporate updates.

Keep reading...Show less
Tinley's Files Interim Results and Announces Investor Call

Tinley's Files Interim Results and Announces Investor Call

The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB: TNYBF) ("Tinley's" or the "Company") announces the filing of its interim consolidated financial statements and management's discussion and analysis for the three and nine month periods ended September 30, 2023, which are available on SEDAR at The Company also announces that an investor call has been scheduled to update Tinley's shareholders and the marketplace on various initiatives currently being undertaken that are intended to create substantial value for its shareholders. To fund these near-term value creating opportunities, the Company will need to complete a financing.

Keep reading...Show less

Trulieve Announces Completion of Redemption of All US$130 Million 9.75% Senior Secured Notes due 2024

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has completed the redemption of all US$130,000,000 (Cdn$175,669,000) principal amount of its outstanding 9.75% senior secured notes due 2024 (CUSIP: 89788CAB0 ISIN: CA89788CAB06) (the "Notes"). Cash used for the redemption was approximately US$136 million ( Cdn$184 million ), which included the aggregate principal amount of the Notes being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date of December 1, 2023 . The Notes will cease to trade on the Canadian Securities Exchange under the symbol "TRUL.DB.U" as of the close of trading on December 1, 2023 and will be delisted as of December 1, 2023 .  Additional information regarding the redemption of the Notes is available from Odyssey Trust Co.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Maple leaf over cannabis leaves.

Cannabis Stocks: 10 Biggest Companies

The cannabis industry faced similar obstacles in 2023 as it did in 2022, with a lack of reform both in the United States and Canada proving to be a significant roadblock to growth in the market.

With the year almost behind us, here the Investing News Network recounts the performance of some of the largest cannabis stocks out there.

This list was put together based on the top-weighted pure cannabis stocks included in the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS) and the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) as of November 30, 2023. Share information for companies is accurate as of November 30.

Keep reading...Show less

Cronos Group Inc. enters into agreement for the sale-leaseback of its Stayner, Ontario facility

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") today announced that its wholly owned subsidiary entered into an agreement (the "Sale Agreement") with Future Farmco Canada Inc. (the "Buyer"), a vertical farming company, for the sale and leaseback of its property located at 4491 Concession 12 Sunnidale Road, Stayner, Ontario, Canada, L0M 1S0 (the "Peace Naturals Campus"). Pursuant to the terms of the Sale Agreement, the Buyer has agreed to acquire the Peace Naturals Campus for C$23 million cash, subject to the terms and conditions set forth therein. The parties also plan to enter into a lease agreement upon closing for portions of the Peace Naturals Campus, ensuring continued operations.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
cannabis leaves, statue of liberty

Cannabis Weekly Round-Up: New York Aims to Ease Banking Barriers, Wisconsin Issues Pardons

Cannabis businesses in New York are set to receive easier access to banking services.

Meanwhile, Wisconsin's governor was in a giving mood this week — ahead of the Thanksgiving holiday, he granted pardons to dozens of people with with cannabis-related convictions.

Read on to learn what else happened in the cannabis space this week.

Keep reading...Show less

Latest Press Releases

Related News